Analystreport

Allogene Therapeutics (NASDAQ:ALLO) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report